Research i_need_contribute
Salvia miltiorrhiza improves Alzheimer's disease
source:NCBI 2020-11-18 [Research]
A protocol for systematic review and meta-analysis

Ying Guo, MD,a Xing Dong, MD,a Renyan Zhang, MD,a Yanmei Zhong, MD,b Peng Yang, MD,a,d andSan Ying Zhang, PhDc,∗

Author information Article notes Copyright and License information Disclaimer

aSchool of Basic Medical Sciences

bSchool of Medical Information Engineering, Chengdu University of Traditional Chinese Medicine

cInnovative Institute of Chinese Medicine and Pharmacy of Chengdu University of Traditional Chinese Medicine

dRehabitation Department of Chengdu Fifth People's Hospital, Chengdu, Sichuan, China.

∗Correspondence: San Ying Zhang, Innovative Institute of Chinese Medicine and pharmacy, Chengdu University of Traditional Chinese Medicine, No.1166 Liu-tai avenue, Wenjiang District, Chengdu, Sichuan, China (e-mail:nc.ude.mctudc@yszmct); Peng Yang, Rehabitation Department of Chengdu Fifth People's hospital, No. 33 Mashi Road, Wenjiang District, Chengdu, Sichuan, China (e-mail: moc.621@yszmct).

 

 

Abstract

Background:

Alzheimer's disease (AD) is an age-related neurodegenerative disease that is slowly becoming a global problem. Salvia miltiorrhiza (SM) has a history of thousands of years of use in China. In recent years, SM has been reported to have the effect of improving Alzheimer's disease. However, there is no systematic review of its efficacy and safety yet. Therefore, we propose a systematic review to evaluate the efficacy and safety of SM for AD patients.

Methods:

Six databases will be searched: China National Knowledge Infrastructure (CNKI), China Biological Medicine (CBM), China Scientific Journals Database (CSJD), Wanfang database, PubMed, and EMBASE. The information is searched from January 2010 to July 2020. Languages are limited to English and Chinese. The primary outcomes include changes in the Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) and Activities of Daily Living scale (ADL). Additional outcomes include clinical effective rate and adverse event rate. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system will be used to assess the strength of the evidence.

Results:

This systematic review will evaluate the efficacy and safety of SM in the treatment of Alzheimer's disease.

Conclusion:

This systematic review provides evidence as to whether SM is effective and safe for Alzheimer's disease patients.

Systematic review registration:

INPLASY202070066.

Keywords: Alzheimer's disease, protocol, randomized controlled trials, Salvia miltiorrhiza meta-analysis, systematic review